Perioperative mFOLFOX6 for GE Junction Adenocarcinoma
For locally advanced gastroesophageal junction adenocarcinoma, perioperative FLOT (docetaxel-oxaliplatin-5-fluorouracil) is the current standard of care, not mFOLFOX6, and should be used with durvalumab when available 1.
Current Standard Regimen
The 2026 ESMO guidelines explicitly state that for locally advanced (≥cT2 or cN+, M0) gastroesophageal adenocarcinoma, perioperative FLOT with radical surgery is the standard of care chemotherapy-based approach 1. The addition of durvalumab to FLOT (D-FLOT) followed by durvalumab maintenance is now the preferred option when available 1.
Why FLOT Over mFOLFOX6
- FLOT4 trial established FLOT superiority over older regimens (ECF/ECX) with improved overall survival and pathologic complete response rates 2
- ESOPEC trial demonstrated FLOT's superiority over chemoradiotherapy (CROSS regimen) for overall survival in GEJ adenocarcinoma 2
- FLOT includes docetaxel, which mFOLFOX6 lacks—this triplet drug combination provides superior efficacy
When mFOLFOX6 May Be Considered
mFOLFOX6 is relegated to a second-line alternative only when patients are unsuitable for FLOT 1. The guidelines specifically state: "Patients unsuitable for both FLOT and CRT may receive an oxaliplatin-fluoropyrimidine doublet" 1.
mFOLFOX6 Dosing (When Used)
Based on research evidence, the standard mFOLFOX6 regimen consists of 3, 4:
- Oxaliplatin 85 mg/m² IV over 2 hours
- Leucovorin 400 mg/m² IV over 2 hours
- 5-FU 400 mg/m² IV bolus
- 5-FU 2400 mg/m² continuous infusion over 46 hours
- Administered every 2 weeks
Perioperative Schedule for mFOLFOX6
- Preoperative: 3-4 cycles (6-8 weeks)
- Surgery: 4 weeks after last chemotherapy cycle
- Postoperative: 2-4 cycles starting 4-8 weeks after surgery
Clinical Outcomes with mFOLFOX6
Research data shows mFOLFOX6 achieves 3, 5:
- R0 resection rates: 95-100%
- Pathologic response (≥50% regression): 49-90%
- Pathologic complete response: 21%
- 3-year overall survival: 92.3%
- Feasibility: 92% complete preoperative treatment
Toxicity Profile
Grade 3-4 toxicities with mFOLFOX6 include 3, 5, 4:
- Neutropenia: 33-34%
- Neuropathy: 20.5%
- Neutropenic fever: reported but uncommon
- Thromboembolism: 7.7%
Modified FLOT Dosing (Preferred Standard)
Recent real-world data demonstrates that dose-modified FLOT maintains efficacy while improving tolerability 6:
- Fluorouracil 2400 mg/m² over 46-48 hours (reduced from standard 2600 mg/m²)
- Oxaliplatin 85 mg/m²
- Docetaxel 40-50 mg/m² (reduced from standard 50 mg/m²)
- Every 2 weeks
This modified FLOT achieved 88% R0 resection, 16% pCR, and 3-year OS of 75.3% with manageable toxicity 6.
Immunotherapy Integration
The treatment landscape has shifted with immunotherapy 1, 2:
- MATTERHORN trial demonstrated that durvalumab plus perioperative FLOT significantly improved event-free survival, establishing D-FLOT as the new emerging global standard 7
- This represents the most recent advancement and should be prioritized when available
Critical Caveats
- mFOLFOX6 lacks docetaxel, which is a key component of the superior FLOT regimen
- Use mFOLFOX6 only if patient has contraindications to docetaxel or FLOT is unavailable
- For patients with PD-L1-positive tumors unsuitable for FLOT, consider preoperative chemoradiotherapy followed by surgery and adjuvant nivolumab (if R0 resection with residual disease) 1
- Do not use mFOLFOX6 as first choice—it represents a compromise when standard therapy cannot be delivered
Algorithm for Treatment Selection
- First choice: Perioperative FLOT + durvalumab (D-FLOT) if available 1
- Second choice: Perioperative FLOT alone if durvalumab unavailable 1
- Third choice: Preoperative chemoradiotherapy + surgery + adjuvant nivolumab (if PD-L1+ and unsuitable for FLOT) 1
- Fourth choice: Oxaliplatin-fluoropyrimidine doublet (mFOLFOX6) if unsuitable for both FLOT and CRT 1
The evidence is clear: FLOT-based regimens are superior to mFOLFOX6 for GE junction adenocarcinoma, and mFOLFOX6 should only be used when FLOT cannot be administered.